Ionis EVP Birchler buys 58 shares at $51.31

Ionis Pharmaceuticals’ EVP acquired additional shares via the employee stock purchase plan, which are locked up until late February 2027.

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS INC (IONS) reports that executive vice president Brian Birchler acquired 58 shares of common stock on August 31, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share.

The footnote states these shares may not be sold until February 28, 2027. Following this transaction, Birchler directly holds 102,883 shares of Ionis common stock.

Insider Trade Summary

Other: 58 shares

Other 1 txn

Insider Birchler Brian

Role EVP, Corp and Development Ops

Type	Security	Shares	Price	Value
Other	Common Stock F1	58	$51.306	$3K

Holdings After Transaction: Common Stock — 102,883 shares (Direct)

Footnotes (1)

1. F1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

Key Figures

Shares acquired: 58 shares Purchase price per share: $51.306 per share Holdings after transaction: 102,883 shares +1 more

4 metrics

Shares acquired 58 shares Common stock acquired on August 31, 2026 under the employee stock purchase plan

Purchase price per share $51.306 per share Price for shares acquired on August 31, 2026

Holdings after transaction 102,883 shares Direct ownership of Ionis common stock following the August 31, 2026 acquisition

Sale restriction end date February 28, 2027 Date after which the 58 acquired shares may be sold

Key Terms

Employee Stock Purchase Plan, Common Stock, beneficial ownership

3 terms

Employee Stock Purchase Plan financial

"Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Common Stock financial

"Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

beneficial ownership financial

"Following this transaction, Birchler directly holds 102,883 shares of Ionis common stock."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IONIS PHARMACEUTICALS INC (IONS) disclose for Brian Birchler?

Ionis disclosed that executive vice president Brian Birchler acquired 58 shares of Ionis common stock on August 31, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share.

How many IONS shares does Brian Birchler hold after this reported transaction?

After the reported acquisition, Brian Birchler directly holds 102,883 shares of Ionis Pharmaceuticals common stock, according to the Form 4 disclosure.

At what price were the new IONS shares acquired by Brian Birchler?

The 58 shares of Ionis Pharmaceuticals common stock acquired by Brian Birchler on August 31, 2026 were purchased at $51.306 per share under the company’s employee stock purchase plan.

Are the newly acquired IONS shares by Brian Birchler subject to any holding restrictions?

Yes. A footnote states that the 58 shares purchased under the Ionis Pharmaceuticals Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026 may not be sold until February 28, 2027.

Was Brian Birchler’s IONS stock purchase made under a Rule 10b5-1 trading plan?

No Rule 10b5-1 trading plan is reported for this transaction. The shares were acquired through the Ionis Pharmaceuticals Amended and Restated 2000 Employee Stock Purchase Plan, with a stated sale restriction until February 28, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 08:22 PM EDT Accepted by SEC EDGAR 09/02/2026 - 08:22 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Birchler Brian

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Corp and Development Ops

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		J		58(1)	A	$51.306	102,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

	By: Patrick R. O'Neil, attorney-in-fact For: Brian Birchler	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)